Business Context and Reporting Period
This Form 8-K is a current report filed by Miragen Therapeutics, Inc. (trading symbol: MGEN) on July 19, 2019. The report discloses a corporate governance event regarding the departure of a senior officer. Note: The request metadata references "Viridian Therapeutics, Inc.," but the filing text explicitly identifies the registrant as Miragen Therapeutics, Inc.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on personnel changes and does not contain financial statements or performance metrics.
Material Changes
- Executive Departure: Adam S. Levy resigned from his position as Chief Business Officer.
- Effective Date: The resignation was effective as of July 26, 2019.
- Notice Date: Notice of resignation was delivered on July 15, 2019.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for future guidance, management outlook, specific risks, contingencies, or unusual items related to financial performance. The document is limited to the disclosure of the officer's departure under Item 5.02.
Investor Verification Checklist
- Verify the reason for Adam S. Levy's resignation and whether it was amicable.
- Confirm if a replacement for the Chief Business Officer has been identified or if the role will be restructured.
- Review subsequent filings to assess the impact of this departure on the company's business development strategy.
- Clarify the discrepancy between the requested company name (Viridian Therapeutics) and the filing registrant (Miragen Therapeutics).